Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer

Recruiting now

Conditions studied: Ovarian Cancer

In brief

Identify any significant differences in terms of drug response and survival between the different possible alterations in the BRCA1/2 genes, in order to stratify ovarian cancer patients with a view to increasingly personalised and thus effective therapy.

Key facts

Study ID

NCT06775470

Run by

IRCCS Azienda Ospedaliero-Universitaria di Bologna

People needed

300

Starts

2022-07-01

Expected to finish

2025-12-31

Last updated by the study team

2025-01-15

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• ovarian cancer diagnosis by 31/12/2021;
• BRCA test at the UOC of Medical Genetics of the IRCCS AOU of Bologna Policlinico S.Orsola by 31/12/2021;
• follow-up and/or treatment at Medical Oncology and/or Gynaecological Oncology of the IRCCS Azienda Ospedaliero-Universitaria (AOU) of Bologna for a period of time of at least 1 year and by 31/12/2021 and for a minimum period of 6 months

You may not qualify if…

• ovarian carcinoma of 'mucinous' or 'borderline' histotype.

Where it is running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola — Bologna, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.